BioGaia AB (publ)
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIOGY research report →
Companywww.biogaia.com
BioGaia AB (publ) develops, markets, and sells probiotic products with documented health benefits worldwide. It operates through three segments: Pediatrics, Adult Health, and Other. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula.
- CEO
- Theresa Agnew
- IPO
- 2021
- Employees
- 224
- HQ
- Stockholm, SE
Price Chart
Valuation
- Market Cap
- $1.11B
- P/E
- 41.41
- P/S
- 8.67
- P/B
- 9.80
- EV/EBITDA
- 27.58
- Div Yield
- 2.94%
Profitability
- Gross Margin
- 72.97%
- Op Margin
- 27.22%
- Net Margin
- 21.49%
- ROE
- 26.09%
- ROIC
- 23.23%
Growth & Income
- Revenue
- $1.54B · 8.11%
- Net Income
- $332.76M · -5.30%
- EPS
- $3.29 · -5.46%
- Op Income
- $412.47M
- FCF YoY
- -15.62%
Performance & Tape
- 52W High
- $11.46
- 52W Low
- $8.79
- 50D MA
- $10.75
- 200D MA
- $10.17
- Beta
- 0.74
- Avg Volume
- 49
Get TickerSpark's AI analysis on BIOGY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BIOGY Coverage
We haven't published any research on BIOGY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BIOGY Report →